Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

New This Week On Slingshot Insights SA Premium Service: 12/10/2018

|Includes: Chiasma, Inc. (CHMA), ESPR, INSM
Summary

This week's Marketplace postings includes three interviews with experts discussing assets from CHMA, INSM, ESPR.

This series of instablog posts will highlight the most recently executed transcripts being added to the “Become the Smart Money” , Slingshot Insights Seeking Alpha Premium service. In these blog posts we will give you a bit more information about the subject matter experts we interviewed, the topics covered, and relevant companies. We hope that these brief overviews, combined with our free content and articles, will display what we believe is the content’s unique value to our members. Please don’t hesitate to directly ask us questions at any time via SeekingAlpha Direct message or email to info@slingshotinsights.com.

Why Do Expert Research?

While many individuals we speak to are unaware of the role expert interviews play for many professional investors, it is a $600mm industry. Many funds pay in excess of $100,000 a year just for a relationship with an expert network and over a thousand dollars per call. While these numbers sound staggering, many investors consider them well worth the money. Slingshot Insights’ sharing model has transformed the price of these calls for our customers and now we are making them even more affordable to you on the SeekingAlpha Marketplace for only $75 per month.

Become the newest subscriber to “Become the Smart Money” here and gain access to all of these : Link

Transcript 1:A 2nd Look: Digging into the market potential of Chiasma's MYCAPSSA (oral octreotide) in treating Acromegaly

Ticker: CHMA

Who's the Expert?

  • Professor of Medicine (Endocrinology) at UNAM and Director of the Experimental Endocrinology Unit and Endocrinology Service at Hospital de Especialidades; fellowship trained in molecular neuroendocrinology at Northwestern Feinberg.
  • Manages 650 patients with acromegaly at the Acromegaly Clinic at Hospital de Especilaidades, seeing ~1 or 2 new patients per month.
  • Participated in design of P3 trial for MYCAPSSA, and research focuses on pituitary diseases, particularly acromegaly/gigantism, Cushing’s disease and nonfunctioning pituitary adenomas.

Interview Goal: To understand the Safety and Efficacy of Chiasma's Mycapssa, an oral octreotide capsule for the treatment of acromegaly, through an examination of the results from its Multicenter Phase III Trial.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 2: Evaluating the market for LDL-C lowering medications like Bempadoic Acid from Esperion Therapeutics

Ticker: ESPR

Who's the Expert?

  • Professor of Medicine and Director of the Lipid Clinic at the University of Chicago & founding board member of the National Lipid Association.
  • Has conducted over 1000 clinical trials, published more than 300 medical journal articles and written three books on Lipidology.
  • Research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids.

Interview Goal:To better understand the relative benefits of bempedoic acid over current treatments for hypercholesteremia and the market potential of the product candidate.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 3: Part 2 - Discussing the potential of Insmed's recently approved Arikayce (ALIS) in treating nontuberculous mycobacterial disease (NTM)

Ticker: INSM

Who's the Expert?

  • Professor, Division of Mycobacterial and Respiratory Infections & Director, Adult Infectious Disease Unit at National Jewish Health Medical Research Center/University of Colorado.
  • Currently manages between 300-400 patients with pulmonary NTM and is familiar with the P3 ALIS study.
  • Research focuses on Mycobacterial (TB/nontuberculous) and Respiratory Infections, Allergic Pulmonary Bronchial Aspergillosis, Alpha-1 Antitrypsin Deficiency, Bronchiectasis, Cystic Fibrosis, and Drug-resistant Tuberculosis.

Interview Goal: To continue the conversation and get an expert's thoughts on the recent approval of Insmed's (INSM) drug Arikayce [ALIS] in treating NTM lung infections. This call will explore the market potential and projected adoption in the pulmonary infectious disease space.

Link to original project page on Slingshot Insights with questions asked: link

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.